Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Yes Bank 12.22 2.00
Tata Mot 111.40 1.46
Reliance 2151.15 7.10
State Ba 191.65 0.23
Icici Ba 351.05 2.23
Clear All Clear Last
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
FII Activity
Mutual Fund Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Recent News
Broker Research
Research Tutorial
Discussion Forum
Research Reports
Sector Watch
Economy Watch
Aurobindo Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
Market Lot: 1Face Value: 1ISIN Demat: INE406A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

Business Profile
Aurobindo Pharma (AUROBINDOP) was founded in 1986 by P.V.Ramaprasad Reddy, K.Nityananda Reddy and a small, highly committed set of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.

Aurobindo Pharma is a fast-track integrated pharmaceutical company headquartered in Hyderabad, India, producing and marketing active pharmaceutical ingredients (bulk actives), intermediates and specialty generic formulations.

AUROBINDOP ranks among the top five pharma companies in India and is a multi product, multi technology, transnational company. The company`s products serve consumers in India and over 100 other countries including the markets of United States and Europe.

Aurobindo Pharma is an R&D driven chemistry business house with a very broad product portfolio. The company has a presence in fast growing life style disease drugs, anti infective drugs, and key specialty therapeutics.

Aurobindo Pharma is a known leader in the semi synthetic penicillin and cephalosporin. After creating a name for it in producing APIs and intermediates, the company sees major growth in its specialty generic formulations business. In December 29, 2006, Agile Pharma B.V., the ultimate subsidiary of AUROBINDOP acquired 100% stake in the share capital of Pharmacin International B.V., The Netherlands

AUROBINDOP sees its potential both in regulated and other global markets. In regulated markets, Aurobindo Pharma visualises profits aided by the thrust in building intellectual property. In the large growth segments of other global markets, it will succeed by virtue of its cost-efficient production. The company is based at Hyderabad, India.

The company announced fall of 11.09% in consolidated net profit on y-o-y basis to Rs 5.29 billion, while total income dropped 100.00% y-o-y basis to Rs 0.00 million for the quarter ended March 2018.

Recent Developments
Aurobindo Pharma, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries.

Aurobindo Pharma, announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US.

Aurobindo Pharma has received approval from the South African Health Products Regulatory Authority (SAHPRA) for its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, 50mg/300mg/300mg, the first-line preferred regimen for HIV patients as per latest WHO guidelines.

Aurobindo Pharma announced that wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire certain assets from Sandoz Inc.,

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection, 250 mg/vial.

Aurobindo Pharma announced that its wholly owned step-down subsidiary, Agile Pharma B.V. (Netherlands) has entered into an agreement on 13 July 2018 to acquire commercial operations and certain supporting infrastructure in five European countries viz

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Azithromycin tablets 250 mg and 500 mg. Azithromycin tablets are an AB-rated generic equivalent of Pfizer Inc's Zithromax tablets. The product will be launched in July 2018.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200mg. Aurobindo???s Ibuprofen capsules are a generic equivalent of Pfizer's Advil Liqui-Gels Capsules. The product will be launched in Sep 2018.

In Brief

Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited